Clinical Trial Detail

NCT ID NCT03284424
Title Study of Pembrolizumab (MK-3475) in Adults With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) (MK-3475-629/KEYNOTE-629)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

skin squamous cell carcinoma

Therapies

Pembrolizumab

Age Groups: senior adult

No variant requirements are available.